Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ribosomal protein L23a pseudogene 42 (RPL23AP42) is a processed pseudogene located on chromosome 3q26.1[2][6]. It is one of many pseudogenes related to the ribosomal protein L23a (RPL23A), which encodes a component of the 60S ribosomal subunit involved in ribosome structure and protein synthesis[1][5][7]. Unlike the functional RPL23A gene, RPL23AP42 is classified as a pseudogene and is not expected to produce a functional protein product[2][6]. Pseudogenes such as RPL23AP42 typically arise from duplication or retrotransposition events and generally lack biological function, though some ribosomal protein pseudogenes have been implicated as non-coding RNAs with regulatory potential[3][4]. There is currently no evidence that RPL23AP42 itself is expressed, has a biological function, or is involved in disease, and it is not considered a therapeutic target[2][3][6]. The gene is not linked to any specific safety concerns, biomarker roles, or drug interactions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ribosomal protein L23a pseudogene 42 (RPL23AP42).